13:23 , May 31, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural analyses of an...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Company News

Vertex, Spero Therapeutics deal

Vertex granted Spero worldwide rights to Vertex’s VXc-486/VXc-100 and other undisclosed antibacterial compounds targeting DNA gyrase subunit B (GyrB) and topoisomerase IV Par E subunit (ParE) . Vertex will receive an undisclosed upfront payment and...
08:00 , Nov 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DNA gyrase subunit B (GyrB)

Infectious disease In vitro studies identified azaindole urea GyrB inhibitors that could help treat resistant Gram-positive bacterial infections. Chemical synthesis and in vitro testing of azaindole urea analogs identified several compounds that inhibited GyrB from...
08:00 , Nov 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection DNA gyrase subunit B (gyrB); topoisomerase IV Par E subunit (parE) Rodent and in vitro studies have identified an aminobenzimidazole urea inhibitor...
07:00 , Jul 22, 2013 |  BioCentury  |  Regulation

An incremental GAIN

FDA...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Company News

Biota Pharmaceuticals infectious news

Biota said it will reduce headcount by about 30 (27%) to 80 over the "next several quarters" to save cash. The cuts will be concentrated on R&D functions dedicated to drug discovery, but will also...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

Trius preclinical data

Trius presented preclinical data for several dual inhibitors of the bacterial enzymes DNA gyrase subunit B (GyrB) and topoisomerase IV Par E subunit (ParE) . In a mouse model of Streptococcus pneumoniae lung infection, doses...